Gelonghui, April 22 | Kaituo Pharmaceutical-B (9939.HK) surged 27.59% to HK$1.11 at the beginning of the session. According to the news, the company announced that it has independently developed a novel proteolytic chimeric compound GT20029 targeting androgen receptors. The Chinese phase II clinical trial for topical treatment of male androgenic alopecia has reached the main research end, and will actively deploy subsequent clinical strategies for GT20029, such as carrying out phase III clinical trials in China for male hair loss and phase II clinical trials in the US. Additionally, the company is preparing to conduct a phase II clinical trial of GT20029 for acne treatment.
港股异动丨开拓药业一度大涨27%，治疗脱发药达II期临床试验主要终点
Changes in Hong Kong stocks 丨 Kaituo Pharmaceutical once surged 27%, and the drug to treat hair loss reached the main end point of phase II clinical trials
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.